A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA)

Jared Jagdeo, Derek Ho, Alex Lo, Alastair Carruthers

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.

Original languageEnglish (US)
Pages (from-to)1040-1054
Number of pages15
JournalJournal of the American Academy of Dermatology
Volume73
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Esthetics
HIV
Cheek
Therapeutics
Social Stigma
Highly Active Antiretroviral Therapy
Orbit
United States Food and Drug Administration
Durapatite
Cost-Benefit Analysis
Randomized Controlled Trials
Calcium
Safety
Bone and Bones

Keywords

  • facial volume loss
  • filler agent
  • highly active antiretroviral therapy
  • HIV facial lipoatrophy
  • HIV lipodystrophy
  • quality of life

ASJC Scopus subject areas

  • Dermatology

Cite this

A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA). / Jagdeo, Jared; Ho, Derek; Lo, Alex; Carruthers, Alastair.

In: Journal of the American Academy of Dermatology, Vol. 73, No. 6, 01.12.2015, p. 1040-1054.

Research output: Contribution to journalArticle

@article{933b5af682b24368b811a6a8a0fea24a,
title = "A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA)",
abstract = "HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50{\%}. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.",
keywords = "facial volume loss, filler agent, highly active antiretroviral therapy, HIV facial lipoatrophy, HIV lipodystrophy, quality of life",
author = "Jared Jagdeo and Derek Ho and Alex Lo and Alastair Carruthers",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.jaad.2015.08.040",
language = "English (US)",
volume = "73",
pages = "1040--1054",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA)

AU - Jagdeo, Jared

AU - Ho, Derek

AU - Lo, Alex

AU - Carruthers, Alastair

PY - 2015/12/1

Y1 - 2015/12/1

N2 - HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.

AB - HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.

KW - facial volume loss

KW - filler agent

KW - highly active antiretroviral therapy

KW - HIV facial lipoatrophy

KW - HIV lipodystrophy

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84947779555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947779555&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2015.08.040

DO - 10.1016/j.jaad.2015.08.040

M3 - Article

C2 - 26481056

AN - SCOPUS:84947779555

VL - 73

SP - 1040

EP - 1054

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -